Ventilator-associated pneumonia
ICD-10 J95.8 · ICD-11 CA40&PK81.0

Treatment of Ventilator-Associated Pneumonia Due to ESBL-Producing Gram-Negative Bacilli

Identifying the causative pathogen in VAP as an extended-spectrum β-lactamase (ESBL)–producing gram-negative bacillus significantly shapes antibiotic selection. Empiric coverage alone is insufficient in this setting; definitive therapy must be informed by susceptibility data.

Clinical Scenario

Ventilator-associated pneumonia due to extended-spectrum β-lactamase (ESBL)–producing gram-negative bacilli. Patient-specific factors — including allergies and comorbidities that may increase the risk of adverse effects — are central to treatment decisions in this population.

Approach to Definitive Therapy

Definitive antibiotic selection is guided by the results of antimicrobial susceptibility testing alongside patient-specific factors. A structured, time-limited course is recommended.

Full regimen details, antibiotic options, and duration specifics are available in the complete protocol →

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/cid/ciw353

For patients with HAP/VAP due to ESBL-producing gram-negative bacilli, we recommend that the choice of an antibiotic for definitive (not empiric) therapy be based upon the results of antimicrobial susceptibility testing and patient-specific factors (strong recommendation, very low-quality evidence).

For patients with VAP, we recommend a 7-day course of antimicrobial therapy rather than a longer duration (strong recommendation, moderate-quality evidence).

View source ↗